Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/19211
Title: | Aβ-related memory decline in APOE ε4 noncarriers: Implications for Alzheimer disease. | Austin Authors: | Lim, Yen Ying;Laws, Simon M;Villemagne, Victor L ;Pietrzak, Robert H;Porter, Tenielle;Ames, David;Fowler, Christopher;Rainey-Smith, Stephanie R;Snyder, Peter J;Martins, Ralph N;Salvado, Olivier;Bourgeat, Pierrick;Rowe, Christopher C ;Masters, Colin L ;Maruff, Paul | Affiliation: | Department of Medicine, Austin Health, Heidelberg, Victoria, Australia Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI CogState Ltd., Melbourne, Australia Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth Co-operative Research Centre for Mental Health, Carlton South From The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Australia Department of Psychiatry, Yale University School of Medicine, New Haven, CT Academic Unit for Psychiatry of Old Age, St. Vincent's Health, The University of Melbourne, Kew National Ageing Research Institute, Parkville, Australia Commonwealth Scientific Industrial Research Organization (CSIRO) Preventative Health National Research Flagship, Australian e-Health Research Centre-BiaMedIA, Brisbane Department of Nephrology, Austin Health, Heidelberg, Victoria, Australia |
Issue Date: | 2016 | Date: | 2016 | Publication information: | Neurology 2016; 86(17): 1635-42 | Abstract: | As the absence of Aβ-related memory decline in APOE ε4 noncarriers may be due to the relative brevity of previous studies, we aimed to characterize Aβ-related cognitive decline over 72 months in APOE ε4 carriers and noncarriers who were cognitively normal (CN). CN older adults (n = 423) underwent Aβ imaging and APOE genotyping. Participants completed comprehensive neuropsychological testing at baseline 18-, 36-, 54-, and 72-month assessments. Relative to Aβ- CN ε4 noncarriers, both Aβ+ CN ε4 carriers and noncarriers showed significantly increased decline in measures of memory, language, and executive function as well as higher rates of progression to a clinical classification of mild cognitive impairment. Memory decline was greater in Aβ+ CN ε4 carriers than in Aβ+ CN ε4 noncarriers. No cognitive decline was evident in Aβ- CN ε4 carriers. In CN older adults, Aβ+ is associated with memory decline in ε4 noncarriers; however, the rate of this decline is much slower than that observed in ε4 carriers. These data indicate that the processes by which ε4 carriage increases the rate of Aβ-related cognitive decline occur in the preclinical stage of Alzheimer disease. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/19211 | DOI: | 10.1212/WNL.0000000000002604 | ORCID: | 0000-0003-3910-2453 | Journal: | Neurology | PubMed URL: | 27029632 | Type: | Journal Article |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.